Despite the anti-tumor activity of EZH2 inhibitor that was previously demonstrated in refractory B-cell non-Hodgkin’s lymphoma and epithelioid sarcomas [266], the evaluation of GSK126, an EZH2 inhibitor, in a phase 1 clinical trial in patients with advanced hematologic and solid tumors showed insufficient evidence of clinical activity [267]. Here, EZH2 is linked to B-cell non-Hodgkin lymphoma.